Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
NEW YORK, NY / ACCESS Newswire / November 20, 2025 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...
Pre-earnings options volume in DexCom (DXCM) is 5.0x normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 11.3%, or $7.76, after results are released ...
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know. DexCom beat analysts’ revenue expectations by 2.8% last quarter, ...
Investing.com -- DexCom (NASDAQ:DXCM) stock fell 4% Tuesday after a concerning report from Hunterbrook detailed multiple deaths allegedly linked to the company’s G7 continuous glucose monitor. The ...
SAN DIEGO, October 27, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results